for people ages 2-22 (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Amit Sabnis



This is a 5-part, open-label, Phase 1/1b multicenter, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; 4) non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1 or ALK gene rearrangements; and 5) patients who are otherwise eligible but unable to swallow capsules. The study is designed to explore the safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetics, and antitumor activity of entrectinib.

Official Title

A Phase 1/1 b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS 1, or ALK Fusions


Solid TumorsCNS TumorsNeuroblastomaTRKTyrosine kinaseNTRKNTRK1NTRK2NTRK3ROS1ALKPediatricRelapsedRefractorySolid TumorMetastatic CancerGene rearrangementInfantile fibrosarcomaSecretory breast cancerCongenital mesoblastic nephromaPontine gliomaBrain tumorsSarcomaEwing sarcomaGlial tumorsSalivary Gland Cancer (MASC)Papillary thyroid cancerMedulloblastomaWilms tumor (anaplastic)NeoplasmsCentral Nervous System NeoplasmsEntrectinibExtracranial solid tumors harboring NTRK1/2/3,CNS tumors harboring- NTRK1/2/3, ROS1, ALK


You can join if…

Open to people ages 2-22

  1. Ability to swallow capsules unless enrolled in Part E
  2. Body surface area (BSA): Subjects must have a body surface area ≥ 0.45 m2 at the time of the study enrollment, unless enrolled in Part E
  3. Disease status: Subjects must have measurable or evaluable disease, by RECIST v1.1 ± Curie Scale Criteria or RANO/RANO-BM
  4. Tumor type:
  5. Part A: Relapsed or refractory extracranial solid tumors and (Phase 1b expansion) relapsed or refractory extracranial solid tumors with molecular alterations, non-gene fusions;
  6. Part B: Relapsed or refractory primary CNS tumors with molecular alterations, including gene fusions, documented by a CLIA-approved lab prior to enrollment;
  7. Part C: Relapsed or refractory neuroblastoma;
  8. Part D: Relapsed or refractory non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1, or ALK gene fusions documented by a CLIA-approved lab prior to enrollment;
  9. Part E: Any patient unable to swallow capsules who otherwise meet all other eligibility criteria for Part A (expansion) B, C or D
  10. Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse
  11. Archival tumor tissue from diagnosis or, preferably, at relapse
  12. Age: Male or female age ≥ 2 years and < 22 years unless enrolled in Part E
  13. Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks
  14. Patient's cancer must have relapsed after or failed to respond to frontline curative therapy or there must not be other potentially curative treatment options available
  15. . Adequate organ and neurologic function
  16. . Females of child bearing potential must have a negative serum pregnancy test within 14 days prior to entrectinib dosing

You CAN'T join if...

  1. Receiving other experimental therapy
  2. Known congenital long QT syndrome
  3. Known active infections
  4. Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
  5. Incomplete recovery from acute effects of any surgery prior to treatment.
  6. Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
  7. Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.


  • UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology accepting new patients
    San FranciscoCalifornia94158United States
  • Children'S Hospital of Orange County accepting new patients
    OrangeCalifornia92868-3874United States

Lead Scientist

  • Amit Sabnis
    Authored (or co-authored) 13 research publications


accepting new patients
Start Date
Completion Date
Hoffmann-La Roche
Phase 1
Study Type
Last Updated